NanoViricides, Inc. announced it will present at NIBA's 152nd Investment Conference in Fort Lauderdale on March 12, where President and Executive Chairman Anil R. Diwan will outline progress on the company's broad-spectrum antiviral platform. The company also reported that manufacturing of its NV-387 Oral Gummies drug product has been completed in preparation for patient dosing once clinical sites are ready, as the therapy advances toward a Phase II trial for monkeypox in the Democratic Republic of Congo following a successful Phase I safety study in healthy volunteers.
The completion of NV-387 Oral Gummies manufacturing represents a significant milestone for the clinical stage company that is creating special purpose nanomaterials for antiviral therapy. According to company information available at https://www.nanoviricides.com, NV-387 is a broad-spectrum antiviral drug that the company plans to develop as a treatment for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections. The drug's unique broad-spectrum antiviral properties have shown effectiveness in animal models for Monkeypox (MPox), Smallpox, and Measles, positioning it as a potentially versatile therapeutic option against multiple viral threats.
NV-387 has successfully completed a Phase I human clinical trial in healthy volunteers with no reported adverse events, providing a solid safety foundation for further development. The company is currently focused on advancing NV-387 into Phase II human clinical trials, with the completed manufacturing of the oral gummies formulation representing a crucial step toward this goal. The oral delivery method could offer significant advantages in terms of patient compliance and accessibility, particularly in resource-limited settings like the Democratic Republic of Congo where the monkeypox trial is planned.
The company's other advanced drug candidate is NV-HHV-1 for the treatment of all Herpesvirus infections including HSV-1 "cold sores," HSV-2 "genital ulcers," VZV Shingles and Chickenpox. However, the company cannot project an exact date for filing an Investigational New Drug (IND) application for any of its drugs because of dependence on a number of external collaborators and consultants.
The upcoming presentation at NIBA's investment conference provides an opportunity for the company to showcase its progress to potential investors and stakeholders. For those interested in following company developments, the latest news and updates relating to NNVC are available in the company's newsroom at https://ibn.fm/NNVC. The progress in NV-387 development comes at a time when global health systems continue to face challenges from emerging viral threats, making broad-spectrum antiviral platforms increasingly valuable in pandemic preparedness and response strategies.
The advancement of NV-387 toward Phase II trials for monkeypox treatment has particular significance given the ongoing global health concerns surrounding orthopoxviruses. The Democratic Republic of Congo location for the planned trial represents a region where monkeypox is endemic, potentially providing valuable real-world data on the drug's effectiveness. The successful completion of manufacturing for the oral gummies formulation suggests the company has overcome significant technical challenges in drug formulation and production, moving closer to making the therapeutic available for clinical testing in affected populations.
